Clinical Trial Update: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Palifermin for Toxic Epidermal Necrolysis and Stevens-Johnson syndrome was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stevens-johnson Syndrome
• Toxic Epidermal Necrolysis

Drugs mentioned

• Palifermin (palifermin)

Snippet

Sponsor: Brett King | Conditions: Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-11-30